×
About 3,993 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  1,253 results

Impending central retinal vein occlusion and granulomatous uveitis in a patient with Sa...
https://doi.org/10.1097/MD.0000000000033284
Medicine Saima Y, Tanaka Y et. al.

Mar 18th, 2023 - Satoyoshi syndrome is a rare systemic autoimmune disease that presents with painful muscle spasms. We report a case of impending central retinal vein occlusion (CRVO) secondary to granulomatous pan-uveitis in a 32-year-old woman with Satoyoshi syn...

Two-year outcomes of patients presenting to Sydney Eye Hospital with neovascular glaucoma.
https://doi.org/10.1007/s10792-023-02675-5
International Ophthalmology; Kingston EJ, Lusthaus JA

Mar 14th, 2023 - Neovascular glaucoma (NVG) is a sight-threatening condition that is often refractory to treatment. Current management principles are yet to be standardized due to lack of evidence. We studied the interventions used to treat NVG at Sydney Eye Hospi...

Branch Retinal Vein Occlusion (BRVO)
http://emedicine.medscape.com/article/1223498-overview

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

Branch Retinal Vein Occlusion (BRVO)
https://emedicine.medscape.com/article/1223498-print

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

Branch Retinal Vein Occlusion (BRVO)
https://emedicine.medscape.com/article/1223498-overview

Mar 14th, 2023 - Background Much confusion exists in the literature because central retinal vein occlusions and branch retinal vein occlusions (BRVOs) are often grouped and studied together. The natural history and the complication rate for each entity differ. The...

see more →

Drugs  8 results see all →

Clinicaltrials.gov  229 results

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740905

Mar 8th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion
https://clinicaltrials.gov/ct2/show/NCT03061526

Mar 2nd, 2023 - Several studies tried to classify retinal ischemia due to retinal artery or vein occlusion into different grades. In some cases prognosis is dependent on grade of severity, especially in cases of retinal vein occlusion. State of the art to Diagnos...

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740931

Feb 28th, 2023 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT05532735

Feb 24th, 2023 - Randomised, double-masked placebo controlled study to evaluate safety and proof of concept with ascending doses of ANXV (human recombinant Annexin A5 protein) during 5 consecutive days treatment in patients recently diagnosed with Retinal Vein Occ...

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Feb 17th, 2023 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

see more →

News  103 results

Non-Paxlovid Rebound; Pandemic Spike in Early Puberty; New Therapy for Nightmares?
https://www.medpagetoday.com/infectiousdisease/covid19/101470

Oct 28th, 2022 - Note that some links may require subscriptions. Outpatient COVID treatment with nirmatrelvir-ritonavir (Paxlovid) was 36% and 30% lower for Black and Hispanic patients compared with white patients, a CDC report found. A high proportion of recovere...

Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma
https://www.onclive.com/view/sequential-treatment-with-immunotherapy-and-targeted-therapy-denotes-os-benefit-in-braf-mutant-melanoma

Sep 27th, 2022 - Immunotherapy in the form of ipilimumab (Yervoy) plus nivolumab (Opdivo) followed by the targeted therapy combination encorafenib (Braftovi) plus binimetinib (Mektovi) elicited an overall survival (OS) benefit in patients with untreated BRAF-mutat...

FDA OKs First Interchangeable Ranibizumab Biosimilar
https://www.medpagetoday.com/ophthalmology/generalophthalmology/100045

Aug 3rd, 2022 - The FDA has approved the first interchangeable biosimilar to the ophthalmologic anti-VEGF agent ranibizumab (Lucentis), Coherus BioSciences announced. The approval of ranibizumab-eqrn (Cimerli) covers all five current FDA-approved indications for ...

New Tissue-Agnostic Treatment Options Emerge
https://www.onclive.com/view/new-tissue-agnostic-treatment-options-emerge

Aug 2nd, 2022 - The menu of tissue-agnostic oncology drug approvals is growing, generating new treatment options for patients with rare cancers and strengthening the rationale for broad next-generation sequencing (NGS), experts say. In June 2022, the FDA approv...

COVID-19 May Increase Risk for Rare Eye Clots
https://www.medscape.com/viewarticle/972265

Apr 18th, 2022 - (Reuters) - Patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward, new findings suggest. Because SARS-CoV-2 infections increase the risk of blood vessel obstructions at other sites...

see more →

Patient Education  4 results see all →